

Orchids as Potential Sources of Anticancer Agents: Our Experience

Bijaya Pant^{1,2}, Mukti Ram Paudel¹, Pusp Raj Joshi^{1,2}

¹Central Department of Botany, Tribhuvan University, Kirtipur, Kathmandu, Nepal

²Annapurna Research Center, Maitighar, Kathmandu, Nepal

CORRESPONDENCE

Prof. Bijaya Pant
Central Department of Botany,
Tribhuvan University, Kirtipur,
Kathmandu, Nepal
Email: b.pant@cdbtu.edu.np

ARTICLE INFO

Article History

Submitted: 01 October, 2020

Accepted: 29 December, 2020

Published: 8 February, 2021

Source of support: None

Conflict of Interest: None

Copyright : ©The Author(S) 2020

This is an open access article under the Creative Commons Attribution license CC-BY 4.0



ABSTRACT

Cancer is the second leading cause of death globally and the cancer burden continues to grow, exerting tremendous physical, emotional and financial strain on individuals, families, communities and health systems. Many health systems in low- and middle-income countries are ill-prepared to manage this burden, and around the world large numbers of cancer patients do not have access to timely quality diagnosis or treatment. Natural products, especially originated from plants, have been applied as remedies to treat various diseases, including cancer, for thousands of years. Several anticancer agents derived from plants, such as paclitaxel (taxol), vinblastine, vincristine, camptothecin derivatives, podophyllotoxins, are in clinical use and a number of other promising agents are in preclinical or clinical development. A growing number of bioactive compounds with cytostatic and cytotoxic activities to treat cancer have been isolated from several orchid species. The Annapurna Research Center in collaboration with other academic institutions is engaged in identifying and exploring anticancer compounds in orchids of Nepal. The center has identified ten different orchid species which contain high phenol and flavonoid contents evidently showing anticancer activities in our *in vitro* assays against different cancer cell lines viz cervical cancer, lung cancer and brain tumor cell lines. These findings demonstrate that orchids which have been used in various formulations in traditional medicine since ancient times qualify as potential source for novel drug candidates or starting points for further lead optimization towards clinical candidates for the most urgently needed treatment of aggressive types of cancer. This review paper highlights that in all likelihood; our contributions in orchid research here in Nepal could bring great relief to patients with cancer globally.

Key words: Cancer; Orchids; Anticancer compounds; Natural products

INTRODUCTION

Cancer is a group of over 100 disease types leading to abnormal invading cell growth, which spreads to other parts in the body, referred to as metastasizing. Metastases are a major cause of death from cancer. Globally, cancer is one of the leading causes of death. Worldwide, one in five men and one in six women develop cancer during their lifetimes. The five-year-prevalence figure is estimated to be 43.8 million cases globally and is expected to rise by additional 22 million annually within the next two decades.¹ The International Agency for Research on Cancer (IARC) released on 14th December the updated Globocan 2020 with new estimates on the global cancer burden, indicating that it has risen to 19.3 million cases and 10 million cancer deaths in 2020.² Treatment of cancer currently includes the surgical removal of cancerous tissue, radiotherapy, chemotherapy and a combination of chemotherapy and targeted therapy. Many health systems in low- and middle-income countries are least prepared to manage this burden, and large numbers

of cancer patients globally do not have access to timely quality diagnosis and treatment. The WHO reported that 30% of the deaths from cancer are preventable if people would not consume tobacco products and if they would eat a healthy diet, exercise regularly, limit the use of alcohol and protect themselves against cancer-causing infections.¹ The utilization of anti-cancer drugs in chemotherapy, while often more beneficial when used in conjugation with radiation therapy or surgery, is considered the first line of treatment. Because cytotoxic drugs are the mainstay of chemotherapy, it is important to discover novel cytotoxic or cytostatic agents with sufficient activity, novel mechanisms-of-action and minimal issues of toxicity and amenable to targeted therapies.^{3,4,5}

Natural products, especially derived from plants, have been used to treat various diseases for thousands of years. The world market for medicinal plants and their products is increasing with rapidly escalating prices. The demand

for medicinal plants intended for use by traditional Ayurveda and modern pharmaceutical companies as source for novel drug candidates is on the rise. Therefore, the trade of medicinal plants becomes an important source of revenue to the Nepal government and supports substantially the livelihoods of communities, particular in rural settings. Medicinal plants have enormous therapeutic potential and may have few side effects.⁶ The search for anticancer agents from plant sources started back in the 1950s, when cytotoxic vinca alkaloids (vinblastine and vincristine) and podophyllotoxins (etoposide and teniposide) were isolated.⁷ Furthermore, several anticancer agents derived from plants, including taxol (*Taxus brevifolia*), vinblastine and vincristine (*Catharanthus roseus*), camptothecin derivatives (*Camptotheca acuminata*), podophyllotoxins (*Podophyllum peltatum*) are in clinical use, and followed by a number of promising agents in preclinical or clinical development. Examples are flavopiridol, roscovitine, combretastatin A-4, betulinic acid and silvestrol. Since synthetic anticancer drugs are expensive and not easy to access for everybody in Nepal. There is a need to search for novel anticancer compounds in plants, particular herbs, which are rich in compounds with high polyphenol and flavonoid contents. Compounds rich in polyphenol and flavonoids exhibit high antioxidant activities, which property plays an important role for the treatment of cancers.⁸



Figure 1: Some orchid species of anticancer sources; *Dendrobium longicornu* (a), *D. transparens* (b), *Rhyncostylis retusa* (c) and *Vanda cristata* (d).

For this reason, Annapurna Research Center, in collaboration with various other academic institutions, is engaged in identifying and exploring anticancer

compounds isolated from orchids, which are used in traditional medicine in various formulations. The center examines *in vitro* dose-dependent effects of orchid extracts with a high phenol and flavonoid content against cancer-cell lines, namely for glioblastoma, cervical and lung cancer. It is determined whether or not the compounds extracted arrests the proliferation of cancerous cells. In result ten different orchid species were identified where their extracts demonstrated strong antiproliferative activities in the assays. Some orchids of Nepal (Fig.1) have already been investigated for their anticancer activity in different cancer-cell lines.⁸⁻¹¹ Once there is a suggestion that antioxidants and anticarcinogens do indeed exist in a particular plant, it has been investigated further, using crude extracts from various plant parts as well as *in vitro* culture-raised tissue. Moreover, the center is conserving the germplasm of species with anticancer potential using *in vitro* culture technologies. Some of the species are amenable to mass propagation. Such highly interesting process of cultivation has been exercised in a partnering mode with different stakeholders of society.

Anticancer agents from orchids

A large number of bioactive compounds with anticancer and anti-tumorous activities have been isolated from several orchid species (Table 1). The methanolic extract obtained from *Anoectochilus formosanus* have shown to induce apoptosis of MCF-7 cells. Antitumor activity of *A. formosanus* may be associated with its potent immune stimulating effect.¹² A phenanthrene derivative 3,7-dihydroxy-2,4,6-trimethoxyphenanthrene was isolated from the all plant of *Bulbophyllum odoratissimum*. The compound displayed cytotoxicity against the growth of human leukemia cell lines K562 and HL-60, human lung adenocarcinoma A549, human hepatoma BEL-7402 and human stomach cancer cell lines SGC-7901 with IC₅₀ values of 14.23, 10.02, 3.42, 15.36 and 1.13 mg/ml respectively.¹³ A number of compounds such as 7,8-dihydro-4-hydroxy 12,13-methylenedioxy-11-methoxydibenz[bf]oxepin, cumulating, densiflorol A and plicatol B isolated from *Bulbophyllum kwangtungense* have shown anti-tumor activities against Hela and K562 human tumor cell lines (Wang et al., 2006). Silbenoids, 3,3'-dihydroxy-2',6'-bis(p-hydroxybenzyl)-5-methoxybibenzyl and 3',5'-dihydroxy-2-(p-hydroxybenzyl)-3-methoxybibenzyl isolated from the tubers of methanol extract of *Bletilla striata* showed inhibitory effect of tubulin polymerization at IC₅₀ 10 μ M. On the other hand, phenanthrene and dihydrophenanthrene with a benzyl moiety (1-(p-hydroxybenzyl)-4,8-imethoxyphenanthrene-2,7-diol and 2,7-dihydroxy-1,3-bis(phydr-oxybenzyl)-4-methoxy-9,10-dihydrophenanthrene), and dimeric

phenanthrenes blestriarenes B and C and blestrianol A were found to be three times less potent (IC₅₀: 30 μM) than bisbenzyls indicating that the restricted diaryl ring system of phenanthrene is unfavorable for tubulin binding. Furthermore, bisbenzyl 3,3'-dihydroxy-2',6'-bis(p-hydroxybenzyl)-5-methoxybibenzyl potentiated the cytotoxicity of SN-38 in BCRP-transduced K562 (K562/BCRP) cells.¹⁴ Studies were also carried out on microspheres of tubers of *B. striata* on angiogenesis. It produced a change of tumor microcirculation after transcatheter arterial chemoembolization: first pass perfusion MR imaging and Chinese ink casting in a rabbit model. With Bletilla microspheres may enhance its anti-tumor effect by inhibiting the angiogenesis (Zhao et al., 2004). The same observations have been made in other experiment when tested *B. striata* colloid on angiogenesis. Inhibits angiogenesis, through binding inhibition of vascular endothelial growth factor to its receptor.¹⁵

The tuber of *Cremastra appendiculata* yield cirrhopedalanthrin and 2,7,2',7',2''-pentahydroxy-4,4',4''7''-tetramethoxy-1,8,1',1''-triphenanthrene which were found to have moderate cytotoxicity against human colon cancer, human stomach cancer, human hepatoma, human breast cancer, human lung adenocarcinoma and human ovarian cancer cell lines.¹⁶ The homoisoflavanone 5,7-dihydroxy-3-(3-hydroxy-4-methoxybenzyl)-6-methoxychroman isolated from *C. appendiculata* was found to be a potent inhibitor of angiogenesis.¹⁷ Cephalinone F isolated from *Cephalanceropsis gracilis*, a native orchid of Taiwan, has significant cytotoxicity against human breast carcinoma (MCF-7), lung carcinoma (NCI-H460), and central nervous system carcinoma (SF-268) cell lines. Cirrhopedalanthrin isolated from tuber of *Cremastra appendiculata* showed non-selective moderate cytotoxicity with IC₅₀ values of 8.4-13.3 μM against human colon cancer (HCT-8), human hepatoma (Bel7402), human stomach cancer (BGC-823), human lung adenocarcinoma (A549), human breast cancer (MCF-7) and human ovarian cancer (A2780) cell lines.¹⁷ A study to understand the molecular basis underlying the antitumor effects of *C. appendiculata* was performed by 5,7-dihydroxy-3-(3-hydroxy-4-methoxybenzyl)-6-methoxychroman isolated from the bulb. Similar observations were obtained in a study with the ethanol extract of the tuber of *C. appendiculata* was subjected to column chromatography to yield 2,7,2',7',2''-pentahydroxy-4,4',4''7''-tetramethoxy-1,8,1',1''-triphenanthrene and cirrhopedalanthrin. Both compounds were evaluated against six human cancer cells; human lung adenocarcinoma (A549), human ovarian cancer (A2780), hepatoma (Bel7402), human stomach cancer (BGC-283), human colon cancer (HTC-8), and human breast cancer (MCF-7) cell lines. Both compounds

were selectively active against the human cancer cell lines used.¹⁶

Denbinobin and 4,7-dihydroxy-2-methoxy-9,10-dihydrophenanthrene from *Dendrobium nobile* showed cytotoxicity against human lung carcinoma, human ovary adenocarcinoma and human promyelocytic leukemia cell lines.¹⁷ Erianin obtained from the stem of *Dendrobium chrysanthum* was found to be a potent inhibitor of proliferation of HL-60 cells and the inhibition might be due to erianin-induced apoptosis and altered expression of bcl-2 and bax genes in HL-60 cells.¹⁸ In another study, erianin leads to extensive tumor necrosis, growth delay and rapid vascular shutdown in hepatoma Bel7402 and melanoma A375.¹⁹ Dendrochrysanene isolated from stems of *D. chrysanthum* was found to suppress the mRNA level of TNF-alpha, IL8, IL10 and iNOS in murine peritoneal macrophages.²⁰ Two pimarane diterpenoids, lonchophylloids A and B were isolated from the stems of *Ephemerantha lonchophylla* expressed the multidrug resistance phenotype to the toxicity of the anticancer isolated from the stems of *Ephemerantha lonchophylla* expressed the multidrug resistance phenotype to the toxicity of the anticancer drug doxorubicin. Subsequently, it has been reported that denbinobin also isolated from this plant exhibit anti-tumor and anti-inflammatory activity. Denbinobin displays anticancer effects in K562 cells through the increase of levels of tubulin polymerization and deregulation of BcrAbl signaling (Huang et al., 2005). Methanolic extract of *Gastrodia elata* prevents serum deprived apoptosis through activation of serine/threonine kinase dependent pathway and suppression of JNK activity.²¹ whereas the ethanolic extract from the rhizomes have shown potent anti-tumor activity in vitro in a dose dependent manner.²² According to Huang et al. (2007), bis-(4-Hydroxybenzyl) sulfide and N6-(4-hydroxybenzyl) adenine riboside were isolated from methanol extract of rhizomes of *G. elata* potentially prevented PC12 cell apoptosis on ischemic/hypoxic model to screen neuroprotective in concentration dependent manners with EC₅₀ values of 7.20 μM and 3.7 x 10⁻⁸ M, respectively. (2S)5,2',6'-trihydroxy-6-lavandulyl-4''-(γ,γdimethylallyl)-2'',2''-dimethylpyrano-[5'',6'',7,8] flavanone, a dihydroflavanoid isolated from *Spiranthes australis* inhibits human cancer cells growth including A498, A549, BEL-7402,SGC-7901,MCF-7, HT-29 and K562 cell lines.²³

Table 1: Anticancer effect of extracts/compounds of different orchid species on different cancer cell lines.

S.N.	Orchid Species	Extract/Active Compound	Biological Target	References
1	<i>Agrostophyllum brevipes</i>	Callosinin		Majumder et al., 2001,2003 ^{24,25}
2	<i>Anoectochilus formosanus</i>	Methanolic extract	MCF-7 cell lines	Tseng et al., 2006 ²⁶
3	<i>Bletilla formosana</i>	4-Methoxy-9,10-dihydrophenanthrene-1,2,7-triol 1-(4-Hydroxybenzyl)-4,7-dimethoxy-9,10-dihydrophenanthrene-2-ol 1,3,6-tri(4-Hydroxybenzyl)-4-methoxydihydrophenanthrene-2,7-diol		Lin et al., 2005 ²⁷
4	<i>B. striata</i>	3,3'-Dihydroxy-2',6'-bis(p-hydroxybenzyl)-5-methoxybibenzyl 3',5-Dihydroxy-2-(p-hydroxybenzyl)-3-Methoxybibenzyl 1-(p-Hydroxybenzyl)-4,8-dimethoxyphenanthrene-2,7-ol 2,7-Dihydroxy-1,3-bis(p-hydroxybenzyl)-4-methoxy-9,10-dihydrophenanthrene Blestrianol A Blestriarene B Blestriarene C	K562 cell line	Morita et al., 2005 ¹⁴
5	<i>Bulbophyllum kwangtungense</i>	Plicatol B Cumulatin Densiflorol A	Hela and K562 cell lines	Wu et al., 2006 ²⁸
6	<i>B. odoratissimum</i>	3,7-Dihydroxy-2,4,6-trimethoxyphenanthrene	K562, HL-60, A549, BEL-7402 and SGC-7901 cell lines	Chen et al., 2007 ¹³
7	<i>Coelogyne cristata</i>	Coeloginanthridin Coeloginanthrin		Majumder et al., 2001 ²⁴
8	<i>C. flaccida</i>	Callosinin		Majumder et al., 2001,2003 ^{24,25}
9	<i>C. stricta</i>	Methanol extract	HeLa cell line	Thapa et al., 2020 ¹⁰
10	<i>Cremastra appendiculata</i>	Cirrhopetalanthin 2,7,2',7',2''-Pentahydroxy-4,4'',7''-tetramethoxy-1,8,1',1''-triphenanthrene	HCT-8, Bel7402, BGC-823, A549, MCF-7 and A2780 cell lines	Xue et al., 2006 ¹⁶
11	<i>Dendrobium amoenum</i>	Methanol extract	HeLa and U-251 cell lines	Paudel & Pant, 2017 ²⁹
12	<i>D. brymerianum</i>	Moscaticilin Gigantol Lusianthrindin Dendroflorin	H460 cell line	Klongkumnuankarn et al., 2015 ³⁰
13	<i>D. catenatum</i>	Protein extract Peptides	HepG2, SGC-7901, MCF-7 cell lines	Zheng et al., 2015 ³¹
14	<i>D. crepidatum</i>	Methanol extract Ethanol extract	HeLa, U-251 cell lines and T-cell lymphoma	Paudel et al., 2019 ³² ; Prasad & Koch, 2016 ³³
15	<i>D. chrysanthum</i>	Ethanol extract Moscaticilin	T-cell lymphoma and FaDu cell line	Nam et al., 2019 ³⁴ ; Prasad & Koch, 2016 ³³
16	<i>D. chryseum</i>	Methanol extract	HeLa and U251 cell lines	Pant et al., 2021 ¹¹

17	<i>D. chrysotoxum</i>	Erianin 1,4,5-trihydroxy-7-methoxy-9H-fluoren-9-one Dendroflorin Chrysotoxol B Confusarin Moscatin Epheranthol B Erianin Gigantol Tristin	T47D, 143B, HUVECs, HeLa, MG63.2, K562, HL-60, A549, BEL-7402, SGC-7901 cell lines	Chen et al., 2008 ³⁵ ; Hu et al., 2012 ³⁶ ; Li et al., 2018 ³⁷ ; Sun et al., 2016 ³⁸ ; Wang et al., 2016 ³⁹ Lin et al., 2005 ²⁷
18	<i>D. denneanum</i>	Polysaccharides	S180 induced mice	Fan & Luo, 2011 ⁴⁰
19	<i>D. densiflorum</i>	Cypripedin	H460 cell line	Wattanathamsan et al., 2018 ⁴¹
20	<i>D. draconis</i>	Gigantol	H460 cell line	Charoenrungruang et al., 2014a ⁴² , 2014b ⁴³ ; Unahabhokha et al., 2016 ⁴⁴
21	<i>D. ellipsophyllum</i>	4,5,4'-trihydroxy-3,3'-dimethoxybibenzyl	H460, H292, H23 cell lines	chaotham & Chanvorchote 2015 ⁴⁴ ; Chaotham et al. 2014 ⁴⁵ ; Hlosrichok et al., 2018 ⁴⁶
22	<i>D. falconeri</i>	Dendrofalconerol A	H460 cell line	Pengpaeng et al., 2014 ⁴⁷ , 2015 ⁴⁸
23	<i>D. fimbriatum</i>	4-(3-hydroxy-4-methoxyphenethyl)-2,6-dimethoxyphenol Fimbriadimerbibenzyl A, B, E, F and G Moscatilin	HL-60, SMMC-7721, A-549, SW480, MCF-7 cell lines	Xu et al., 2014 ⁴⁹
24	<i>D. findlayanum</i>	4, 4'-dihydroxy-3, 3',5-trimethoxy bibenzyl	A172, SHSY5Y and HeLa cell lines	Liu et al., 2020 ⁵⁰
25	<i>D. formosum</i>	Ethanol extract	T-cell lymphoma	Prasad & Koch, 2014 ⁵¹
26	<i>D. gratiosissimum</i>	Dengraols A and B Gigantol Moscatilin	HL-60	Zhang et al., 2008 ⁵²
27	<i>D. loddigesii</i>	Moscatilin	HUVECs, A-549, H23, MDA-MB-231, HCT-116, SCC, A375 cell lines	Cardile et al., 2020 ⁵³ ; Chen et al., 2013 ⁵⁴ ; Chen et al., 2008 ⁵⁵ ; Ho & Chen, 2003 ⁵⁶ ; Kowitdamrong et al., 2013 ⁵⁷ ; Tsai et al., 2010 ⁵⁸
28	<i>D. longicornu</i>	Acetone extract Ethanol extract	U-251 and HeLa cell lines	Paudel et al., 2017 ²⁹
29	<i>D. moniliforme</i>	Methanol extract Ethanol extract Denbinobin Moniliformediquinone	HeLa, HCT-116, MCF-7, U-251, K562, HSC-T6, BNL CL.2, PC-3 and DU-145 cell lines, 26-M3.1 induced mice	Hsu et al., 2014 ⁵⁹ ; Huang et al., 2005 ⁶⁰ ; Li et al., 2014 ⁶¹ ; Paudel et al., 2018 ⁶² ; Sánchez-Duffhues et al., 2009 ⁶³ ; Sun et al., 2016 ⁶⁴ ;
30	<i>D. nobile</i>	Denbinobin Denobilone A Lactone derivatives Polysaccharides	K562, PC-3, SNU-484, SK-Hep-1, HeLa, MCF-7, A549, HL-60, HepG2 cell lines and S180 induced mice	Huang et al., 2005 ²³ ; Lu et al., 2014; ⁶⁶ Luo & Fan, 2011 ⁶⁷ ; Song et al., 2012 ⁶⁸ ; Wang et al., 2010 ⁶⁹ ; Zhou et al., 2016 ⁷⁰
31	<i>D. officinale</i>	Aqueous extract 4,4'-dihydroxy-3,5-dimethoxybibenzyl Dendrocandin B Dendrocandin U Denofficin Gigantol Moscatilin Polysaccharides	MNNG-induced gastric tumorigenesis in rats, HeLa cell line, and SGC-7901 xenograft mice	Ren et al., 2020 ⁷¹ ; Zhang et al., 2018 ⁷² ; Zhao et al., 2016 ⁷³

Orchids as Potential Sources of Anticancer Agents

32	<i>D. polyanthum</i>	Moscatilin	A549, HL-60 cell lines	Hu et al., 2009 ⁷⁴
33	<i>D. pulchellum</i>	Chrysotoxine	H460, H23 cell lines	Bhummaphan et al., 2018; ⁷⁵ Chanvorachote et al.,
		Moscatilin		
34	<i>D. signatum</i>	Ethanol extract	MCF-7, NCI-H187, MDA-231, HepG2 and HT-29 cell lines	Chimsook, 2016 ⁷⁷ ; Mittraphab et al., 2016 ⁷⁸
		Dendrosignatol		
		3,4-dihydroxy-3',4'-dimethoxybibenzyl		
		Dendrocandin B		
		dendrocandin I		
		Dendrofalconerol A		
35	<i>D. sinense</i>	3,4,3'-trimethoxy-5,4'-dihydroxybibenzyl	SGC-7901, BEL-7402, K562 cell lines	Chen et al., 2014 ⁷⁹
		5,3'-dihydroxy-3,4-dimethoxy-bibenzyl		
		Longicornuol A		
36	<i>D. transparens</i>	Methanol extract	HeLa and U251 cell lines	Joshi et al., 2020 ⁹
37	<i>Ephemerantha lonchophylla</i>	Ephemeranthone	K562 cell line	Chen et al., 2000 ⁸⁰
		Erianthridin		
		Denbinobin		
38	<i>Eulophia macrobulbon</i>	Ethanol extract and fractions	MCF-7, HeLa and CaCo-2 cell lines	Schuster et al., 2017 ⁸¹
39	<i>E. nuda</i>	9,10-dihydro-2,5-dimethoxyphenanthrene-1,7-diol	MCF-7 and MDA-MB-231 cell lines	Shriram et al., 2010 ⁸² ; Bhatt et al., 2018 ⁸³
		Alcohol extract		
40	<i>Gastrodiaelata</i>	N6-(4-hydroxybenzyl) adenine riboside	PC12 cell line	Huang et al., 2004 ²¹
41	<i>Gymnadeniaconopsea</i>	Gymconopin A		Matsuda et al., 2004 ⁸⁴
		Gymconopin B		
		Gymconopin D		
		Dihydroxy-2,6-bis(4-hydroxybenzyl)-5-methoxy-bibenzyl		
42	<i>Maxillaria densa</i>	2,5-Dihydroxy-3, 4-Dimethoxyphenanthrene		Decigsa-campos et al., 2007 ⁸⁵
		9,10-dihydro-2,5-dihydroxy-3, 4-dimethoxyphenanthrene		
		Nudol		
		Gymnopusin		
		Erianthridin		
		Fimbriol A		
43	<i>Papilionanthe uniflora</i>	Methanol extract	HeLa cell line	Joshi et al., 2020 ⁹
44	<i>Pholidota articulata</i>	Methanol extract	HeLa cell line	Joshi et al., 2020 ⁹
45	<i>P. yunnanensis</i>	2,4,7-Trihydroxy-9,10-Dihydrophenanthrene		Guo et al., 2007 ⁸⁶
		3,7-dihydroxy-2,4,8-Trimethoxyphenanthrene		
		Coelonin		
		3,7-Dihydroxy-2,4-dimethoxyphenanthrene		
46	<i>Rhyncostylis retusa</i>	Methanol extract		Radhika et al., 2013 ⁸⁷
47	<i>Spiranthes australis</i>	(2S)-5,2',6'-trihydroxy-6-lavandulyl-4''-(γ,γ-dimethylallyl)-2'',2''-dimethylpyrano-[5'',6'': 7,8]-flavanone	A549, BEL-7402, SGC-7901, MCF-7, HT-29, K562, and A498 cell lines	Peng et al., 2007 ²³
48	<i>Vanda cristata</i>	Methanol extract	HeLa and U251 cell lines	Joshi et al., 2020

CONCLUSION

It is documented that orchids are rich in potential anticancer agents and are on the forefront in terms of offering possibilities for new anticancer drugs. Many existing anticancer remedies based on traditional medicine are of orchid origin. In fact, orchids have exhibited anticancer activities in animal models of leukemia, skin cancer and sarcomas. For those plants which have shown promising results, further investigation has ensued but deeper investigations for single active molecular moiety must be undertaken. While cancer exerts a high mortality rate and may not be treatable by the usual arsenal of an oncologist, it is likely that orchids and their components may play a role in palliative care or reduce the side effects associated with currently available cancer treatments. By generating awareness regarding the use of herbs and exploring their natural product properties, healthcare professionals can play a significant critical role as knowledge resource for the masses. From literature-based information, our research findings show that particular orchids, used since ancient times in traditional medicine under various formulations, contain potential anticancer drug candidates in their plant material and may also experience eventual utilization as herbal product, depending on the specific data collected.

ACKNOWLEDGEMENT

The authors gratefully acknowledge Dr. Sven H Wagner for the constructive feedback and suggestions on the manuscript.

REFERENCES

1. Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. *CA: a cancer journal for clinicians*. 2018;68(6), 394-424.
2. Siegel RL, Miller KD, Goding SA, Fedewa SA, Butterly LF, Anderson JC, Jemal A. Colorectal cancer statistics, 2020. *CA: a cancer journal for clinicians*. 2020; 70(3), 145-164.
3. Guilbaud N, Kraus BL, Meyer LF, Malivet V, Chacun C, Jan M, Atassi G. Marked antitumor activity of a new potent acronycine derivative in orthotopic models of human solid tumors. *Clinical Cancer Research*, 2011;7(8), 2573-2580.
4. Moraes DFC, Mesquita LSS, Amaral FM, Malik S. Anticancer drugs from plants. In *Biotechnology and Production of Anti-Cancer Compounds*. 2017; (pp. 121-142). Springer, Cham.
5. Greenwell M, Rahman PK. Medicinal plants: their use in anticancer treatment. *International Journal of Pharmaceutical Sciences and Research*. 2015; 6(10), 4103.
6. Vital PG, Rivera, WL. Antimicrobial activity and cytotoxicity of *Chromolaena odorata* (L. f.) King and Robinson and *Uncaria perrottetii* (A. Rich) Merr. Extracts. *Journal of medicinal plants Research*. 2009; 3(7), 511-518
7. Gordon MC, David J. Plants as a source of anti-cancer agents. *Journal of Ethnopharmacology*. 2005; 100, 72.
8. Paudel MR, Bhattarai HD, Pant B. Traditionally used medicinal *Dendrobium*: a promising source of active anticancer constituents. *Orchids Phytochemistry, Biology and Horticulture: Fundamentals and Applications*. 2020; 1-26.
9. Joshi PR, Paudel MR, Chand MB, Pradhan S, Pant KK, Joshi GP, Pant B. Cytotoxic effect of selected wild orchids on two different human cancer cell lines. 2020; 6(5), e03991.
10. Thapa, BB, Thakuri LS, Joshi PR, Chand K, Rajbahak S, Sah AK, Pant B. *Ex-situ* conservation and cytotoxic activity assessment of native medicinal orchid: *Coelogyne stricta*. *Journal of Plant Biotechnology*. 2020; 47(4), 330-336
11. Pant B, Joshi PR, Maharjan S, Thakuri LS, Pradhan S, Shah S, Pant B. Comparative Cytotoxic Activity of Wild Harvested Stems and *In Vitro*-Raised Protocorms of *Dendrobium chryseum* Rolfe in Human Cervical Carcinoma and Glioblastoma Cell Lines. *Advances in Pharmacological and Pharmaceutical Sciences*, 2021.
12. Chaotham C, Chanvorachote P. A bibenzyl from *Dendrobium ellipsophyllum* inhibits migration in lung cancer cells. *Journal of Natural Medicines*. 2015; 69, 565-574.
13. Chen YG, Xu JJ, Yu H, Qing C, Zhang YL, Liu Y, Wang JH. 3, 7-Dihydroxy-2, 4, 6-trimethoxyphenanthrene, a new phenanthrene from *Bulbophyllum odoratissimum*. *Journal of the Korean Chemical Society*. 2007;51(4), 352-355.
14. Morita H, Koyama K, Sugimoto Y, Kobayashi JI. Antimitotic activity and reversal of breast cancer resistance protein-mediated drug resistance by stilbenoids from *Bletilla striata*. *Bioorganic & Medicinal Chemistry Letters*. 2005;15(4), 1051-1054
15. Feng GS, Li X, Zheng CS, Zhou CK, Liu X, Wu HP. Mechanism of inhibition of tumor angiogenesis by *Bletilla colloid*: an experimental study. 2003; 83(5), 412-416.
16. Xue Z, Li S, Wang S, Wang Y, Yang Y, Shi J, He L. Mono-, bi-, and triphenanthrenes from the tubers of *Cremastra appendiculata*. *Journal of Natural Products*. 2006;69(6), 907-913

17. Lee YH, Park JD, Beak NI, Kim SI, Ahn BZ . In vitro and in vivo antitumoral phenanthrenes from the aerial parts of *Dendrobium nobile*. *Planta Medica*.1995; 61(02), 178-180.
18. Li Y, Wang H, & Liu G. Erianin induces apoptosis in human leukemia HL-60 cells. *Acta Pharmacologica Sinica*.2001; 22(11), 1018-1022.
19. Gong YQ, Fan Y, Wu DZ, Yang H, Hu ZB, Wang ZT. In vivo and *in vitro* evaluation of erianin, a novel anti-angiogenic agent. *European Journal of Cancer*.2004.
20. Yang L, Qin LH, Bligh SA, Bashall A, Zhang CF, Zhang M, & Xu LS. A new phenanthrene with a spiro lactone from *Dendrobium chrysanthum* and its antiinflammatory activities. *Bioorganic & Medicinal Chemistry Letters*.2006; 14(10), 3496-3501
21. Huang NK, Lin YL, Cheng JJ, Lai WL. *Gastrodia elata* prevents rat pheochromocytoma cells from serum-deprived apoptosis: the role of the MAPK family. *Life Sciences*.2004; 75(13), 1649-1657
22. Heo JC, Woo SU, Son M, Park JY, Choi WS, Chang KT, Lee, SH. Anti-tumor activity of *Gastrodia elata* Blume is closely associated with a GTP-Ras dependent pathway. *Oncology Reports*.2007; 8(4), 849-853.
23. Peng J, Xu Q, Xu Y, Qi Y, Han X, Xu L. A new anticancer dihydroflavonoid from the root of *Spiranthes australis* (R. Brown) Lindl. *Natural Product Research*.2007;21(7), 641-645.
24. Majumder PL, Sen S, Majumder S. Phenanthrene derivatives from the orchid *Coelogyne cristata*. *Phytochemistry*.2007;58(4), 581-586.
25. Majumder PL, Majumder S, Sen S. Triterpenoids from the orchids *Agrostophyllum brevipes* and *Agrostophyllum callosum*. *Phytochemistry*.2003;62(4), 591-596.
26. Tseng CC, Shang HF, Wang LF, Su B, Hsu CC, Kao HY, Cheng KT. Antitumor and immunostimulating effects of *Anoectochilus formosanus* Hayata. *Phytomedicine*.2006;13(5), 366-370.
27. Lin YL, Chen WP, Macabalang AD. Dihydrophenanthrenes from *Bletilla formosana*. *Chemical and pharmaceutical bulletin*.2005; 53(9), 1111-1113.
28. Wu B, He S, Pan YJ. New dihydrodibenzoxepins from *Bulbophyllum kwangtungense*. *Planta Medica*.2006;72(13), 1244-1247.
29. Paudel MR, Chand MB, Pant B, Pant B. Cytotoxic activity of antioxidant-rich *Dendrobium longicornu*. *Pharmacognosy Journal*.2007;9, 499-503.
30. Klongkumnuankarn P, Busaranon K, Chanvorachote P, Sritularak B, Jongbunprasert V, Likhitwitayawuid K. Cytotoxic and antimigratory activities of phenolic compounds from *Dendrobium brymerianum*. *Evidence-Based Complementary and Alternative Medicine*. 2015;350-410.
31. Zheng Q, Qiu D, Liu X, Zhang L, Cai S, Zhang X. Antiproliferative effect of *Dendrobium catenatum* Lindley polypeptides against human liver, gastric and breast cancer cell lines. *Food & function*,2015; 6(5), 1489-1495.
32. Paudel MR, Chand MB, Pant B, Pant B. Assessment of antioxidant and cytotoxic activities of extracts of *Dendrobium crepidatum*. *Biomolecules*.2019;9, 478.
33. Prasad R, Koch B. In vitro anticancer activities of ethanolic extracts of *Dendrobium crepidatum* and *Dendrobium chrysanthum* against T-cell lymphoma. *Journal of Cytology & Histology*.2016;7,432.
34. Nam B, Ryu SM, Lee D, Jung CH, Jin CH, Kim JB, Han AR. Identification of two new phenanthrenes from *Dendrobii Herba* and their cytotoxicity towards human hypopharynx squamous carcinoma cell (FaDu). *Molecules*.2019;24, 2339
35. Chen TH, Pan SL, Guh JH, Liao CH, Huang DY, Chen CC, Teng CM. Moscatilin induces apoptosis in human colorectal cancer cells: a crucial role of c-Jun NH2-terminal protein kinase activation caused by tubulin depolymerization and DNA damage. *Clinical Cancer Research*.2008;14, 4250-4258.
36. Hu J, Fan W, Dong F, Miao Z, Zhou J . Chemical Components of *Dendrobium chrysotoxum*. *Chinese Journal of Chemistry*.2012; 30, 1327-1330.
37. Li M, He Y, Peng C, Xie X, Hu G. Erianin inhibits human cervical cancer cell through regulation of tumor protein p53 via the extracellular signal regulated kinase signaling pathway. *Oncology Letters*.2018;16, 5006-5012.
38. Sun J, Guo Y, Fu X, Wang Y, Liu Y, Huo B, Hu X . *Dendrobium candidum* inhibits MCF-7 cells proliferation by inducing cell cycle arrest at G2/M phase and regulating key biomarkers. *OncoTargets and Therapy*.2016;9, 21-30.
39. Wang H, Zhang T, Sun W, Wang Z, Zuo D, Zhou Z, Hua Y. Erianin induces G2/M-phase arrest, apoptosis, and autophagy via the ROS/JNK signaling pathway in human osteosarcoma cells in vitro and in vivo. *Cell Death and Disease*.2016; 7, e2247.
40. Fan Y, Luo A. Evaluation of anti-tumor activity of water-soluble polysaccharides from *Dendrobium denneanum*. *African Journal of Pharmacy and Pharmacology*.2011;5, 415-420.
41. Wattanathamsan O, Treesuwan S, Sritularak B, Pongrakhananon V. Cypripedin, a phenanthrenequinone from *Dendrobium densiflorum*, sensitizes non-small cell lung cancer H460 cells to cisplatin-mediated apoptosis.

- Journal of Natural Medicines,2018.
42. Charoenrungruang S, Chanvorachote P, Sritularak B, Pongrakhananon V. Gigantol-induced apoptosis in lung cancer cell through mitochondrial-dependent pathway. Thai Journal of Pharmaceutical Sciences 2014;38, 67-73.
 43. FanY,LuoA.Evaluationofanti-tumoractivityofwater-soluble polysaccharides from *Dendrobium denneanum*. African Journal of Pharmacy and Pharmacology.2011;5, 415-420.
 44. Unahabhokha T, Chanvorachote P,Pongrakhananon V. The attenuation of epithelial to mesenchymal transition and induction of anoikis by gigantol in human lung cancer H460 cells. Tumor Biology.2016; 37, 8633-8641.
 45. Charoenrungruang S, Chanvorachote P, Sritularak B, Pongrakhananon V .Gigantol-induced apoptosis in lung cancer cell through mitochondrial-dependent pathway. Thai Journal of Pharmaceutical Sciences,.2014;38, 67-73.
 46. Unahabhokha T, Chanvorachote P, Pongrakhananon V. The attenuation of epithelial to mesenchymal transition and induction of anoikis by gigantol in human lung cancer H460 cells. Tumor Biology.2016;37, 8633-8641.
 47. Pengpaeng P, Sritularak B, Chanvorachote P. Dendrofalconerol A sensitizes anoikis and inhibits migration in lung cancer cells. Journal of Natural Medicines, 2014;69, 178-190.
 48. Pengpaeng P, Sritularak B,Chanvorachote P. Dendrofalconerol: A suppresses migrating cancer cells via EMT and integrin proteins. Anticancer Research.2015;35, 201-206.
 49. Xu FQ, Xu, FC, Hou B, Fan WW, Zi CT, Li Y, Zuo ZL. Cytotoxic bibenzyl dimers from the stems of *Dendrobium fimbriatum* Hook. Bioorganic & Medicinal Chemistry Letters, 2014;24, 5268-5273.
 50. Pengpaeng, P, Sritularak B, Chanvorachote P. Dendrofalconerol A sensitizes anoikis and inhibits migration in lung cancer cells. Journal of Natural Medicines, 2014;69, 178-190.
 51. Pengpaeng P, Sritularak B, Chanvorachote P. Dendrofalconerol A suppresses migrating cancer cells via EMT and integrin proteins. Anticancer Research,2015; 35, 201-206.
 52. Zhang CF, Wang M, Wang L, Linuma M, Zhang, M, Xu LS, Wang ZT .Chemical constituents of *Dendrobium gratiosissimum* and their cytotoxic activities. Indian Journal of Chemistry,2008; 47, 952-956.
 53. Cardile V, Avola , Graziano AC, Russo A. Moscatilin, a bibenzyl derivative from the orchid *Dendrobium loddigesii*, induces apoptosis in melanoma cells. Chemico-Biological Interactions.2020;323, 109075.
 54. Charoenrungruang S, Chanvorachote P, Sritularak B, Pongrakhananon V. Gigantol, a bibenzyl from *Dendrobium draconis*, inhibits the migratory behavior of non-small cell lung cancer cells. Journal of Natural Products.2014;77, 1359-1366
 55. Prasad R, Koch B. Antitumor activity of ethanolic extract of *Dendrobium formosum* in T-cell lymphoma: An *in vitro* and *in vivo* study. BioMed research international. 2014; 753451.
 56. Ho CK, Chen CC. Moscatilin from the orchid *Dendrobium loddigesii* is a potential anticancer agent. Cancer Investigation.2003; 21, 729-736.
 57. Chaotham C, Chanvorachote P. A bibenzyl from *Dendrobium ellipsophyllum* inhibits migration in lung cancer cells. Journal of Natural Medicines.2015; 69, 565-574.
 58. Chen CA, Chen CC, Shen CC, Chang HH, Chen YJ. Moscatilin induces apoptosis and mitotic catastrophe in human esophageal cancer cells. 2010;Journal of Medicinal Food.2013;16, 869-877.
 59. Chen Y, Li Y, Qing C, Zhang Y, Wang L, Liu Y. 1,4,5-Trihydroxy-7-methoxy-9H-fluoren-9-one, a new cytotoxic compound from *Dendrobium chrysotoxum*. Food Chemistry.2008;108, 973-976.
 60. Tsai AC, Pan SL, Liao CH, Guh JH, Wang SW, Sun HL, Chang, YL. Moscatilin a bibenzyl derivative from the India orchid *Dendrobium loddigesii*, suppresses tumor angiogenesis and growth in vitro and in vivo. Cancer Letters. 292, 163-170.
 61. Kowitdamrong A, Chanvorachote P, Sritularak B, Pongrakhananon V. Moscatilin inhibits lung cancer cell motility and invasion via suppression of endogenous reactive oxygen species.2013;BioMed Research International, 2013, 765894.
 62. Paudel MR, Chand MB, Pant B, Pant B. Antioxidant and cytotoxic activities of *Dendrobium moniliforme* extracts and the detection of related compounds by GC-MS. BMC Complementary and Alternative Medicine.2018;134.
 63. Hsu JL, Lee YJ, Leu WJ, Dong Y, Pan SL, Uang BJ, Guh JH. Moniliformediquinone induces in vitro and in vivo antitumor activity through glutathione involved DNA damage response and mitochondrial stress in human hormone refractory prostate cancer.2014;The Journal of Urology, 191, 1429-1438.
 64. Zhao X, Sun P, Qian Y, Suo H. D. Candidum has in vitro anticancer effects in HCT-116 cancer cells and exerts in vivo anti-metastatic effects in mice.2014; Nutrition Research and Practice, 8(5), 487.

65. Li G, Sun P, Zhou Y, Zhao X, Chen F. Preventive effects of *Dendrobium candidum* Wall ex Lindl. on the formation of lung metastases in BALB/c mice injected with 26-M3.1 colon carcinoma cells. 2014; *Oncology Letters*, 8, 1879-1885.
66. SánchezDuffhues G, Calzado MA, De Vinuesa AG, Appendino G, Fiebich BL, Loock U, Muñoz E. Denbinobin inhibits nuclear factor- κ B and induces apoptosis via reactive oxygen species generation in human leukemic cells. 2009; *Biochemical Pharmacology*, 77, 1401-1409.
67. Sun J, Fu X, Wang Y, Liu Y, Zhang Y, Hao T, Hu X. Erianin inhibits the proliferation of T47D cells by inhibiting cell cycles, inducing apoptosis and suppressing migration. *American Journal of Translational Research*. 2016; 8, 3077-3086.
68. Wang JH, Luo JP, Zha XQ, Feng BJ. Comparison of antitumor activities of different polysaccharide fractions from the stems of *Dendrobium nobile* Lindl. *Carbohydrate Polymer*. 2010; 79, 114-118. 64.
69. Zhou XM, Zheng CJ, Wu JT, Chen GY, Chen J, Sun CG. Five new lactone derivatives from the stems of *Dendrobium nobile*. *Fitoterapia*. 2016; 115, 96-100.
70. Ren G, Deng WZ, Xie YF, Wu CH, Li WY, Xiao CY, Chen YL. Bibenzyl derivatives from leaves of *Dendrobium officinale*. *Natural Product Communications*. 2020; 15, 1-5.
71. Zhang L, Wang F, Ren X. Inhibitory effect of *Dendrobium officinale* polysaccharide on human gastric cancer cell xenografts in nude mice. *Food Science and Technology*. 2018; 38, 78-83.
72. Zhao Y, Liu Y, Lan XM, Xu GL, Sun YZ, Li F, Liu HN. Effect of *Dendrobium officinale* extraction on gastric carcinogenesis in rats. *Evidence-Based Complementary and Alternative Medicine*. 2016;
73. Hu JM, Zhao YX, Miao ZH, Zhou J. Chemical components of *Dendrobium polyanthum*. *Bulletin of the Korean Chemical Society*. 2009; 30, 2098-2100.
74. Zhang L, Wang F, Ren X. Inhibitory effect of *Dendrobium officinale* polysaccharide on human gastric cancer cell xenografts in nude mice. *Food Science and Technology*. 2018; 38, 78-83.
75. Zhao Y, Liu Y, Lan XM, Xu GL, Sun YZ, Li F, Liu HN. Effect of *Dendrobium officinale* extraction on gastric carcinogenesis in rats. *Evidence-Based Complementary and Alternative Medicine*. 2016.
76. Luo A, Fan Y. Immune stimulating activity of water-soluble polysaccharide fractions from *Dendrobium nobile* Lindl. *African Journal of Pharmacy and Pharmacology*. 2011; 5-625-631.
77. Hsu JL, Lee YJ, Leu WJ, Dong YS, Pan SL, Uang BJ, Guh JH. Moniliformediquinone induces in vitro and in vivo antitumor activity through glutathione involved DNA damage response and mitochondrial stress in human hormone refractory prostate cancer. 2014; *The Journal of Urology*, 191, 1429-1438.
78. Ren G, Deng WZ, Xie YF, Wu CH, Li WY, Xiao CY, Chen YL. Bibenzyl derivatives from leaves of *Dendrobium officinale*. *Natural Product Communications*. 2020; 15, 1-5.
79. Chen XJ, Mei WL, Cai CH, Guo ZK, Song XQ, Dai HF. Four new bibenzyl derivatives from *Dendrobium sinense*. *Phytochemistry Letter*. 2014; 9, 107-112.
80. Cardile V, Avola R, Graziano AC, Russo A. Moscatilin, a bibenzyl derivative from the orchid *Dendrobium loddigesii*, induces apoptosis in melanoma cells. *Chemico-Biological Interactions*. 2020; 323, 109075.
81. Schuster R, Zeindl L, Holzer W, Khumpirapang N, Okonogi S, Viernstein H, Mueller M. *Eulophia macrobulbon*—an orchid with significant anti-inflammatory and antioxidant effect and anticancerogenic potential exerted by its root extract. *Phytomedicine*. 2017; 24, 157-165.
82. Shriram V, Kumar V, Kishor PK, Suryawanshi SB, Upadhyay AK, Bhat MK. Cytotoxic activity of 9, 10-dihydro-2, 5-dimethoxyphenanthrene-1, 7-diol from *Eulophia nuda* against human cancer cells. *Journal of ethnopharmacology*. 128(1), 2010; 251-253.
83. Bhatt, D. R., Jethva, K. D., & Zaveri, M. N. (2018). In-vitro cytotoxicity studies of the therapeutic orchid: *Eulophia nuda*. *Journal of Pharmacognosy and Phytochemistry*. 2018; 7(4), 680-683.
84. Matsuda H, Morikawa T, Xie H, Yoshikawa M. Antiallergic phenanthrenes and stilbenes from the tubers of *Gymnadenia conopsea*. 2004; *Planta medica*, 70(09), 847-855.
85. Déciga-Campos M, Palacios-Espinosa JF, Reyes-Ramírez A, Mata R. Antinociceptive and anti-inflammatory effects of compounds isolated from *Scaphyglottis livida* and *Maxillaria densa*. *Journal of Ethnopharmacology*. 2007; 114(2), 161-168.
86. Guo XY, Wang J, Wang NL, Kitanaka S, Yao XS. 9,10-Dihydrophenanthrene derivatives from *Pholidota yunnanensis* and scavenging activity on DPPH free radical. *Journal of Asian Natural Products Research*. 2007; 9(2), 165-174.
87. Radhika B, Murthy J, Grace DN. Antifungal and cytotoxic activities of medicinal important orchid *Rhynchostylis retusa* Blume. *Internal Journal of Advanced Research*. 2013; 1, 31-35.